SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
SPRUCE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$40.40+0.75 (+1.89%)
Close on Oct 19, 2026
- Market cap
- $98.22M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$117.42 (−74.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
SPRUCE BIOSCIENCES, INC. saw revenue fall 100.0% to $0 over fiscal 2025.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$47.83M
TTM Q2 2026
EPS, diluted
-$41.48
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $98.22M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$51.35M
- EPS, diluted
- -$41.48
- Book value per share
- $34.44
- Diluted shares
- 2M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$47.83M
Net income
-$51.35M
EPS, diluted
-$41.48
Free cash flow
–
Reported periodTrailing twelve months